Subject: (Copy) NIH GUIDE - Vol. 19, No. 13, March 30, 1990
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Thu, 29 Mar 90 08:32 EST

Paul,
 Please post this to the listserver as: nihguide.033090.
     Thanks for all your help.  Have a nice day.
                Dottie
 ---------------------------- Text of forwarded message -----------------------
     
X-comment: NIH Guide (including TOC) contained 15 pages (1200 lines)
X-comment: RFAs described:  AI-90-08, DA-90-12, CA-90-14, NR-90-02, 90-HD/MH-08
NIH GUIDE - Vol. 19, No. 13, March 30, 1990

                                   NOTICES

REVISING THE 398 ...........................................(84/108)......... 1
Division of Research Grants
Index:  DIVISION OF RESEARCH GRANTS

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

EVALUATION IN PRIMATES OF CANDIDATE VACCINES FOR SIMIAN ACQUIRED
IMMUNODEFICIENCY SYNDROME (RFP) ............................(114/151)........ 1
National Institute of Allergy and Infectious Diseases
Index:  ALLERGY, INFECTIOUS DISEASES

THE EFFECT OF SELF-APPLIED FLUORIDE ON THE INCIDENCE OF ROOT CARIES
AND CORONAL CARIES IN AN ADULT POPULATION (RFP) ............(161/190)........ 2
National Institute of Dental Research
Index:  DENTAL RESEARCH

PROGRAM PROJECTS ON AUTOIMMUNE MECHANISMS IN DISEASE (RFA AI-90-08) ......... 2
National Institute of Allergy and Infectious Diseases  (193/328, 1204/1528)
Index:  ALLERGY, INFECTIOUS DISEASES

COOPERATIVE AGREEMENT FOR A RESIDENTIAL DRUG ABUSE TREATMENT RESEARCH
DEMONSTRATION PROGRAM IN THE DISTRICT OF COLUMBIA (RFA DA-90-12) ..(331/520). 4
National Institute on Drug Abuse
Index:  DRUG ABUSE

CANCER PREVENTION AND CLINICAL RESEARCH IN UNDER-SERVED
POPULATIONS (RFA CA-90-14) ..........................(523/580, 1531/2197).... 6
National Cancer Institute
Index:  CANCER

BEHAVIORAL RESEARCH IN SUPPORT OF AIDS PREVENTION (RFA NR-90-02) ............ 7
National Institutes of Health                        (583/687, 2200/2945)
Index:  NATIONAL INSTITUTES OF HEALTH

PERINATAL BEHAVIORAL DEVELOPMENT (RFA 90-HD/MH-08) ..(690/746, 2948/3285).... 8
National Institute of Child Health and Human Development
National Institute of Mental Health
Index:  CHILD HEALTH, HUMAN DEVELOPMENT, MENTAL HEALTH

                        ONGOING PROGRAM ANNOUNCEMENTS

ADAMHA SMALL INSTRUMENTATION GRANT PROGRAM ..........(752/853)............... 9
Alcohol, Drug Abuse, and Mental Health Administration
Index:  ALCOHOL, DRUG ABUSE, MENTAL HEALTH

SPECIAL EMPHASIS RESEARCH CAREER AWARD IN LABORATORY ANIMAL SCIENCE .........10
National Center for Research Resources                (856/967, 3288/3905)
Index:  RESEARCH RESOURCES

NEUROENDOCRINOLOGY OF HUMAN STRESS ...................(970/1179).............12
National Institute of Diabetes, Digestive and Kidney Diseases
Index:  DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES

                                   ERRATUM

NOTICE OF SOLICITATION OF PUBLIC COMMENTS FOR THE NATIONAL PANEL FOR
RESEARCH IN NEUROLOGICAL DISORDERS ...................(1185/1197)............14
National Institute of Neurological Disorders and Stroke
Index:  NEUROLOGICAL DISORDERS, STROKE
     
                                   NOTICES

REVISING THE 398
     
P.T. 34; K.W. 1014002
     
Division of Research Grants
     
An NIH committee, with representatives from other agencies in the Public
Health Service, has begun work on revising the PHS 398 Research Grant
Application Kit. The committee welcomes any suggestions or comments from the
scientific community or from other interested persons regarding ways to
improve the application kit.  Suggestions could concern items such as the page
limitations, appendix material, instructions for filling in items, structure
of the scientific proposal, abstract, use of key words, and the applicant's
professional associates and collaborators.  Other areas of concern could be
the personal data section, as well as the assurances that are requested of the
applicant or applicant organization.  Because of time constraints, these
suggestions or comments must be received by April 19, 1990.  Please send them
to:
     
Dr. Patricia Straat
Chief of the Referral Section
Division of Research Grants
National Institutes of Health
Westwood Building, Room 248
Bethesda, MD  20892

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

EVALUATION IN PRIMATES OF CANDIDATE VACCINES FOR SIMIAN ACQUIRED
IMMUNODEFICIENCY SYNDROME
     
RFP AVAILABLE:  RFP-NIH-NIAID-DAIDS-91-05
     
P.T. 34; K.W. 0715008, 0740075, 0201058
     
National Institute of Allergy and Infectious Diseases
     
The National Institute of Allergy and Infectious Diseases (NIAID) has a
requirement to establish simian immunodeficiency virus (SIV) vaccine
evaluation units (SVEUs) that will conduct vaccine clinical trials on
candidate SIV vaccines.
     
This NIAID-sponsored project will take approximately five (5) years to
complete.  A cost-reimbursement contract is anticipated and two (2) awards are
expected to be made.
     
This is an announcement for an anticipated Request for Proposal (RFP).
RFP-NIH-NIAID-DAIDS-91-05 shall be issued on or about April 10, 1990, with a
closing date tentatively set for May 25, 1990.
     
Requests for the RFP shall be directed in writing to:
     
John M. O'Brien
Contract Management Branch
6003 Executive Blvd.
Control Data Building, Room 214P
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 496-0195
     
To receive a copy of the RFP, please supply this office with two (2)
self-addressed labels.  All responsible sources may submit a proposal which
will be considered.
     
This advertisement does not commit the Government to award a contract.

     

     

             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 1
THE EFFECT OF SELF-APPLIED FLUORIDE ON THE INCIDENCE OF ROOT CARIES AND
CORONAL CARIES IN AN ADULT POPULATION
     
RFP AVAILABLE:  NIH-NIDR-2-90-4R
     
P.T. 34; K.W. 0715148, 0740000, 0411005
     
National Institute of Dental Research
     
The National Institute of Dental Research plans to issue a request for
proposals (RFP) for a five-year clinical investigation to determine the
effectiveness of selected self-applied therapeutic agents in reducing the
incidence of root and coronal caries in an adult population residing in a
suboptimal or non-fluoridated community.  Participants must be selected with
care, based upon relevant characteristics thought to be important factors in
identifying adults at risk for coronal and, especially, root caries.
Projected attrition levels of participants also must be considered in the
selection of a suitable study population.  The Institute plans to make one
award from this solicitation.
     
RFP No. NIH-NIDR-2-90-4R will be available on approximately April 16, 1990,
with a due date for proposals of June 8, 1990.  Written requests for a copy of
the RFP should be sent to:
     
Ms. Marion L. Blevins
Contract Management Section
National Institute of Dental Research
National Institutes of Health
Westwood Building, Room 521
Bethesda, MD  20892

PROGRAM PROJECTS ON AUTOIMMUNE MECHANISMS IN DISEASE
     
RFA AVAILABLE:  AI-90-08
     
P.T. 34; K.W. 0715015, 0715026, 0755030, 0765033, 0710070, 0710030
     
National Institute of Allergy and Infectious Diseases
     
Letter of Intent Receipt Date:  May 4, 1990
Application Receipt Date:  July 10, 1990
     
BACKGROUND INFORMATION
     
The Clinical Immunology Branch of the Division of Allergy, Immunology and
Transplantation (DAIT) of the National Institute of Allergy and Infectious
Diseases (NIAID) supports research on humoral, cellular and molecular
mechanisms of immune system functions in health and disease and the
application of this basic biomedical knowledge to clinically relevant
problems.  This Request for Applications (RFA) is intended to encourage and
invite the development of program project applications from collaborating
basic science research and clinical investigative groups concerned with
integrated studies on autoimmune mechanisms in disease.
     
RESEARCH GOALS AND SCOPE
     
Immune system mediated tissue injury (autoimmunity) is a major area of
endeavor under the purview of the NIAID Clinical Immunology Branch.  Within
this specific research area, the goals of the program projects are:  1)
increased understanding of the etiology and pathogenetic mechanisms involved
in autoimmune diseases; and 2) the generation of an expanded knowledge base
that can be applied to the development of improved measures of diagnosis,
treatment, and prevention of a wide variety of disorders involving
immunologically mediated inflammatory reactions.
     
The design and scope of these program projects are intended to include studies
on all aspects of immune responses responsible for or associated with diseases
involving tissue injury or damage in which a role for elements or functions of
the immune system can be identified.  Broad approaches to research on
autoimmune mechanisms in disease may include studies concerned with relevant
areas of genetics, cell and molecular biology, biochemistry, physiology,
microbiology, and pharmacology.
     
Of special interest to NIAID are program projects with research emphasis in
defined areas of investigation that show promise in elucidation of basic
immune mechanisms and their application to clinical autoimmune disorders.
Recent evidence implicates immune-mediated mechanisms in the pathogenesis of
     
             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 2
diseases of the nervous system, skin, endocrine organs and gastrointestinal
tract.  Thus, in addition to studies of well recognized autoimmune diseases,
e.g., systemic lupus erythematosus, rheumatoid arthritis, antibody-mediated
thrombocytopenia and autoimmune hemolytic anemia, NIAID encourages
investigators to design and develop studies aimed at clarifying the role of
autoimmune mechanisms in endocrine, dermatologic, neurologic and
gastrointestinal disorders.
     
The NIH places special emphasis on the need for inclusion of minorities and
women in studies of diseases which disproportionately affect them and also
urges that applicants give added attention, where feasible and appropriate, to
their inclusion in other clinical studies.  For proposed population-based
studies which include neither women nor minorities, a clear rationale for not
including them must be provided.  In attempting to include either group in a
particular study, attention must be paid to such issues as research design and
sample size.  For further information, consult the statements of NIH policy on
the inclusion of minorities and women in study populations that appeared in
the NIH Guide for Grants and Contracts.  The issue dated September 25, 1987
(Vol 16, No. 32, pp.  3-4), announced the policy on minorities; the one on
women appeared in the issue dated January 23, 1987 (Vol 16, No. 3).
     
MECHANISM OF SUPPORT
     
Program project grants are awarded to an institution on behalf of a program
director for the support of a broadly based, multidisciplinary, long-term
research program that has a specific major objective or basic theme.  A
program project generally involves the organized efforts of groups of
investigators, members of which conduct research projects related to the
overall program objective.  The grant can provide support for the projects and
for certain basic resources shared by individuals in the program project where
the sharing facilitates the total research effort.  Each project supported
under a program project grant is expected to contribute to and be directly
related to the common theme of the program; the projects under the direction
of a principal investigator should demonstrate an essential element of unity
and interdependence.  In FY 1991 the NIAID plans to award at least two program
project grants submitted in response to this RFA and, depending on
availability of funds and scientific merit, more than two.  Requests for
support should be limited to no more than $500,000 direct costs per year.
     
ELIGIBILITY
     
ONLY DOMESTIC INSTITUTIONS ARE ELIGIBLE TO APPLY.
     
METHOD OF APPLYING
     
Applications may be submitted by any domestic public or private nonprofit or
profit-making organizations.  Before preparing an application, the prospective
applicant should request a copy of the NIAID Information Brochure on Program
Project and Center Grants from:
     
Kamal K. Mittal, D.V.M., Ph.D.
Executive Secretary
Allergy, Immunology and Transplantation Research Committee
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Westwood Building, Room 3A-07
Bethesda, MD  20892
Telephone:  (301) 496-3528
     
STAFF CONTACT
     
A more detailed RFA may be obtained from:
     
Howard B. Dickler, M.D.
Chief, Clinical Immunology Branch
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Disease
Westwood Building, Room 755
Bethesda, MD  20892
Telephone: (301) 496-7104
Telefax:  (301) 402-0175
     
Prospective applicants are encouraged to submit a one-page letter of intent by
May 4, 1990, to Dr. Mittal that includes a descriptive title of the overall
proposed research, the name of the Principal Investigator and a list of the
names of key investigators and their institution(s).  The letter of intent is
requested in order to provide an indication of the number and scope of
applications to be reviewed so as to allow early preparations for review, as
     
             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 3
well as to promote early interactions between applicants and NIAID staff.  The
letter of intent is not binding and does not commit the sender to submit an
application, nor is it a requirement for submission of an application.
     
THE RFA LABEL AVAILABLE IN THE 10/88 REVISION OF APPLICATION FORM 398 MUST BE
AFFIXED TO THE BOTTOM OF THE FACE PAGE.  FAILURE TO USE THIS LABEL COULD
RESULT IN DELAYED PROCESSING OF YOUR APPLICATION SUCH THAT IT MAY NOT REACH
THE REVIEW COMMITTEE IN TIME FOR REVIEW.

COOPERATIVE AGREEMENT FOR A RESIDENTIAL DRUG ABUSE TREATMENT RESEARCH
DEMONSTRATION PROGRAM IN THE DISTRICT OF COLUMBIA
     
RFA AVAILABLE:  DA-90-12
     
P.T. 34; K.W. 0404009, 0403004
     
National Institute on Drug Abuse
     
Letter of Intent Receipt Date:  May 12, 1990
Application Receipt Date:  June 12, 1990
     
PURPOSE
     
The purpose of this Request for Applications (RFA) is to award a cooperative
agreement to support a drug abuse treatment research demonstration program in
the District of Columbia.  This program will establish, test and evaluate the
effectiveness of a drug abuse treatment approach based on short-term (i.e., 6
months duration) treatment in a therapeutic community followed by intensive
aftercare in order to examine the effectiveness of this approach in particular
diagnostic and patient/population subgroups.  The District of Columbia was
selected as the site for this model treatment research demonstration project
because of the extent and intensity of the drug abuse problem, availability of
clients, and because the combination of patient subgroups and types of drug
abuse problems lends itself to a research demonstration project that may be
able to be replicated in other parts of the country.  As part of the National
Drug Control Strategy, released in September 1989, Washington, D.C. was
identified as the first site for a model drug treatment demonstration program.
     
This RFA is a joint initiative between the National Institute on Drug Abuse
(NIDA) and the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA)
Office for Treatment Improvement (OTI).  OTI was established to provide
national leadership for the Federal effort to enhance approaches and programs
focusing on the treatment of drug abusers as well as associated problems of
alcoholism and mental illness.
     
Cooperative agreement awards will be made under the authority of section 301
of the Public Health Service Act (42 U.S.C. 241).
     
RESEARCH OBJECTIVES
     
This Cooperative Agreement will provide support for:  (1) a 60-bed residential
treatment facility offering a six-month residential treatment program followed
by a six-month aftercare program; (2) a 20-bed crisis unit to be part of the
facility; and (3) research and treatment costs associated with this program
and comparison subjects assigned to other residential programs in the D.C.
area.  The crisis unit will provide short-term intervention for psychological
or family crises and brief medical detoxification in selected cases but is not
intended to handle medical emergencies.  The research demonstration project
will obtain patients through a Diagnostic, Referral, and Data Management Unit,
to be established under a separate Cooperative Agreement (DA-90-11).
     
This demonstration project will evaluate the comparative effectiveness of this
type of residential treatment for the types of drug abuse clients and problems
that are found in the District of Columbia including psychiatric co-morbidity.
The project will also seek to examine which services are essential components
for achieving therapeutic outcomes for different types of clients/problems, as
well as a number of sub-studies to evaluate such factors as diagnostic and
treatment issues involving particular co-morbidities, and the predictive value
of particular diagnostic subclassifications or instruments with particular
types of clients and forms of services.
     
NIDA will provide space for this facility in a government-owned or leased
building in Washington, D.C.
     
In FY 1990, it is estimated that $2.0 million to $2.5 million will be
available to support one award under this RFA (including direct and indirect

             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 4
costs).  Applicants may request up to 3 years of support.  Annual awards will
be made subject to continued availability of funds and progress achieved.
     
MECHANISM OF SUPPORT:  Cooperative Agreement
     
INCLUSION OF WOMEN IN STUDY POPULATIONS:  Applicants are urged to consider the
inclusion of women in the study populations for all clinical research efforts.
Exceptions would be studies of diseases that exclusively affect males or where
involvement of pregnant women may expose the fetus to undue risks.  Gender
differences should be noted and evaluated.  If women are not to be included, a
clear rationale should be provided for their exclusion.
     
In order to provide more precise information to the treatment community, it is
recommended that publications resulting from ADAMHA-supported research in
which the study population was limited to one sex for any reason other than
that the disease or condition studies exclusively affects that sex, should
state, in the abstract summary, the gender of the population studied, e.g.,
"male patients," "male volunteers," "female patients," "female volunteers."
     
INCLUSION OF MINORITIES IN STUDY POPULATIONS:  Applicants are urged to give
added attention (where feasible and appropriate) to the inclusion of
minorities in study populations for research into the etiology of diseases,
research in behavioral and social sciences, clinical studies of treatment and
treatment outcomes, research on the dynamics of health care and its impact on
disease, and appropriate interventions for disease prevention and health
promotion.  If minorities are not included in a given study, a clear rationale
for their exclusion should be provided.
     
APPLICATION PROCESS
     
Applicants should use grant application form PHS 398 (Rev.  10/88).  The
number (DA-90-12) and title of this RFA, "Cooperative Agreement for a
Residential Drug Abuse Treatment Research Demonstration Program in the
District of Columbia," should be typed in item 2 on the face page of PHS 398
form.  Applicants must affix the RFA label, which is provided in the PHS 398
application kit, to the bottom of the face page of the application.  Failure
to use this label could result in delayed processing of the application so
that it may not reach the review committee in time for review.
     
Application kits containing the necessary forms may be obtained from business
offices or offices of sponsored research at most universities, colleges,
medical schools, and other major research facilities.  If such a source is not
available, the following office may be contacted for the necessary application
material:  Grants Management Branch, National Institute on Drug Abuse, 5600
Fishers Lane, Room 8A-54, Rockville, Maryland 20857, (301) 443-6710.
     
Prospective applicants are asked to submit a letter of intent.  This should be
brief but indicate the Principal Investigator and Co-Investigators, and should
identify cooperating institutions, if any.  The Institute requests such
letters only for the purpose of providing an indication of the number and
scope of applications to be received and, therefore, usually does not
acknowledge their receipt.  A letter of intent is not binding and will not
enter into the review of any application subsequently submitted, nor is it a
necessary requirement for applications.  This letter of intent, which should
be received by May 12, 1990, should be sent to:
     
Dr. Michael S. Backenheimer
Acting Director, Office of Extramural Program Review
National Institute of Drug Abuse
5600 Fishers Lane, Room 10-42
Rockville, MD  20857
     
The signed original and 5 permanent, legible copies of the completed
application should be sent to:
     
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
     
It is suggested that a copy of the application also be sent separately to Dr.
Michael Backenheimer, at the address shown above, so that a timely review may
be arranged.
     
REVIEW PROCESS
     
The Division of Research Grants, NIH, serves as a central point for receipt of
applications for most discretionary PHS grant programs.  Applications received
     
             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 5
under this RFA will be assigned to an Initial Review Group (IRG) in accordance
with established PHS Referral Guidelines.  The IRGs, consisting primarily of
non-Federal scientific and technical experts, will review the applications for
scientific and technical merit.  Notification of the review recommendations
will be sent to the applicant after the initial review.  Applications will
receive a second-level review by the National Advisory Council on Drug Abuse
whose review may be based on policy considerations as well as scientific
merit.  Only applications recommended for approval by the Council may be
considered for funding.
     
INTERGOVERNMENTAL REVIEW
     
The intergovernmental review requirements of Executive Order 12372, as
implemented through DHHS regulations at 45 CFR Part 100, are applicable to
applications submitted in response to this RFA.  Through this process, States,
in consultation with local governments (or in this case, the D.C. Government),
are provided the opportunity to review and comment on applications for Federal
financial assistance.  Applicants should contact the District of Columbia
Single Point of Contact (SPOC) listed below as early as possible to determine
the applicable procedure:  Ms. Lovetta Davis, D.C. State Single Point of
Contact, Executive Office of the Mayor, Office of Intergovernmental Relations,
Room 416, District Building, 1350 Pennsylvania Avenue, N.W., Washington, D.C.
20004, Telephone:  (202) 727-9111.
     
AVAILABILITY OF FUNDS
     
In FY 1990, it is estimated that $2.0 million to $2.5 million will be
available to support one award under this RFA (including direct and indirect
costs).
     
INQUIRIES
     
Further information about this project may be obtained from:
     
Frank M. Tims, Ph.D.
Deputy Chief, Treatment Research Branch
Division of Clinical Research, NIDA
5600 Fishers Lane, Room 10A-30
Rockville, MD  20857
Telephone:  (301) 443-4060

CANCER PREVENTION AND CLINICAL RESEARCH IN UNDER-SERVED POPULATIONS
     
RFA AVAILABLE:  CA-90-14
     
P.T. 34, FF; K.W. 0715035, 0785035, 0745027, 0745035, 0795003, 0710030
     
National Cancer Institute
     
Letter of Intent Receipt Date:  May 15, 1990
Application Receipt Date:  August 8, 1990
     
The Special Populations Studies Branch of the Division of Cancer Prevention
and Control, National Cancer Institute (NCI), announces the availability of a
Request for Applications (RFA) on the above subject.  Awards will not be made
to foreign institutions.
     
The Division of Cancer Prevention and Control (DCPC), NCI, invites grant
applications from investigators interested in conducting a coordinated and
systematic program in cancer prevention and clinical research for under-served
populations.  The term "under-served populations" refers to those population
segments that may experience, or are known to experience, higher than average
U.S. general population cancer rates and are under-served in terms of access
to quality comprehensive cancer prevention, screening and early detection, and
treatment services.
     
The goal of a cancer control and prevention research program for under-served
populations is to provide a mechanism to allow the implementation of a
systematic and coordinated research effort to reduce cancer incidence,
mortality and to improve survival rates in under-served low-income high-risk
populations.  By rapid dissemination of state-of-the-art cancer prevention and
control technology a significant effect can be achieved in reducing cancer
mortality in minority and under-served patients through increased accrual to
clinical trials and participation in screening and early detection programs.
     
The term "under-served populations" refers to those population segments that
may experience, or are known to experience, higher than U.S. general
     
             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 6
population cancer rates and are under-served in terms of access to quality
comprehensive cancer prevention, screening and early detection, and treatment
services.  Under-served populations may include, but are not limited to,
groups with concentrations of individuals with low-income, Blacks, Hispanics,
Asian refugees, American Indians, elderly, Hawaiian Natives, and Alaskan
Natives.  They may also include communities where comprehensive cancer
services are unavailable whether the communities are in urban centers or in
rural areas.  Consideration should be given to an adequate representation of
women within these groups.
     
Requests for copies of the RFA should be addressed to:
     
Chief
Special Populations Studies Branch
Division of Cancer Prevention and Control
National Cancer Institute
Executive Plaza North (EPN), Room 240
9000 Rockville Pike
Bethesda, MD  20892-4200
Telephone:  (301) 496-8589

BEHAVIORAL RESEARCH IN SUPPORT OF AIDS PREVENTION
     
RFA AVAILABLE:  NR-90-02
     
P.T. 34; K.W. 0715008, 0404000, 0745027, 0411005, 0404009
     
National Institutes of Health
     
Application Receipt Date:  July 10, 1990
     
Purpose
     
The Agency for International Development (A.I.D), the National Center for
Nursing Research (NCNR), the National Institute on Aging (NIA), and the
National Institute of Child Health and Human Development (NICHD), in
consultation with the National Institutes of Health Office of AIDS Research
(OAR) and the Fogarty International Center (FIC), invite applications for
basic research projects that will provide information concerning high-risk
behaviors and behavioral changes relating to the transmission of Human
Immunodeficiency Virus (HIV) throughout the life course; and strengthen
developing-country capabilities to design and carry out behavioral research to
reduce transmission of Human Immunodeficiency Virus (HIV) infection.
     
SCOPE
     
Research under this Request for Applications (RFA) should be theoretically
grounded and conducted in collaboration with developing country counterparts.
Research areas include:  studies of multiple-partner behavior which would help
to define the determinants, frequency, and distribution of such behavior and
identify those aspects of the behavior that are most amenable to sustainable
change; studies of intravenous drug use that would help to define the context
of drug use, particularly with respect to needle-sharing behaviors, and the
relationships between drug use and sexual transmission; studies of use of
condoms and/or spermicides for AIDS prevention that would define attitudes and
practices related to such use, particularly in various cultural contexts; and
studies of cultural practices that may enhance the risk of sexual
transmission, alter the protection offered by condoms, or may affect the
ability to sustain risk-reducing behaviors.  Studies should seek to identify
approaches to behavior change.
     
Study populations should include those most likely to be practicing high-risk
behaviors in selected developing countries including individuals with multiple
sexual partners, intravenous drug users and their sexual and needle-sharing
partners, sexual partners of persons receiving contaminated blood or blood
products, patients from sexually transmitted disease clinics, or others whose
behaviors place them at high risk for sexually transmitting HIV infection or
becoming infected.  Research to identify other undefined risk groups and
related behaviors should be included.  Where feasible and appropriate,
attempts should be made to insure that study populations include the full
spectrum of HIV-infected individuals of the specific culture where the study
is proposed.
     
Studies are encouraged that incorporate innovative research methods such as
improvements in methods for assessing behavioral determinants, for monitoring
patterns of risk behavior and behavior change, for collecting and validating
self-reported behavioral data, and for evaluating the effectiveness of
intervention activities.
             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 7
The projects will be single projects that consist of activities to take place
in two phases.  Phase I will consist of a preliminary feasibility study for
the larger body of work to be undertaken in Phase II.  It is expected that
Phase I funding will be for up to 12 months, and Phase II funding will be for
up to three additional years.  Each Phase should have well-defined goals,
objectives, and outputs.  Awardees will develop a working relationship with a
developing country counterpart during Phase I and will also establish the
technical and scientific feasibility of successful completion of the entire
project.
     
MECHANISM AND SCALE OF SUPPORT
     
Support for this program will be divided by phase.  Phase I will be funded by
A.I.D. through Family Health International (FHI), and support for Phase II
will be either by grants from the Institutes or Centers of the National
Institutes of Health (NIH) or by A.I.D. through FHI.  Awards made by the NIH
will be administered under PHS grants policy as stated in the Public Health
Service Grants Policy Statement, DHHS Publication No. (OASH) 82-50,000,
revised January 1, 1987.
     
It is not expected that all of the awarded Phase I studies will be extended
into Phase II.  Extension will be based on success in Phase I; review
procedures and criteria for extension are described in the RFA.  Funding of
Phase II studies will also be based on programmatic relevance to a particular
funding agency.
     
Up to approximately six pilot studies in Phase I will be funded ($50,000 to
$85,000 of total costs for up to 12 months).  The anticipated funding level
for Phase II for those studies approved for continuation is $150,000 to
$200,000 per year for up to three additional years for total (direct and
indirect) costs.  It is expected that up to six Phase II projects will be
funded.  All awards under this RFA are contingent on the availability of
funds, and the specific amount to be awarded will depend on the merit and
scope of the applications received.
     
APPLICATION
     
Applicants should submit a single proposal fully describing research
activities for both Phase I and Phase II.  Potential applicants are advised to
obtain the full RFA and an application package from:
     
Ms. Nancy Hardy
Family Health International
1611 N. Kent Street
Suite 903
Rosslyn, VA  22209-2169
Telephone:  (703) 243-8510

PERINATAL BEHAVIORAL DEVELOPMENT
     
RFA AVAILABLE:  90-HD/MH-08
     
P.T. 34; K.W. 0715020, 0775000, 0414012, 0404004, 0755020
     
National Institute of Child Health and Human Development
National Institute of Mental Health
     
Application Receipt Date:  July 31, 1990
     
The Human Learning and Behavior Branch of the Center for Research for Mothers
and Children of the National Institute of Child Health and Human Development
(NICHD), National Institutes of Health (NIH), and the Behavioral Sciences
Research Branch of the Division of Basic Brain and Behavioral Sciences of the
National Institute of Mental Health (NIMH), Alcohol, Drug Abuse, and Mental
Health Administration (ADAMHA), jointly invite investigator-initiated research
applications (R01) to develop new methods, theories, and knowledge on aspects
of behavioral development during the perinatal period.  The aim is to
encourage psychobiological studies, theoretically or empirically based, on the
ontogeny of behavior (e.g., learning, memory, motivation, attachment, and
sensorimotor functioning) during the prenatal and early postnatal periods.
Major foci are upon the use of animal models and interdisciplinary
methodological approaches.  Selected studies of human perinates will also be
considered.  Up to six applications may be funded in connection with this
Request for Applications (RFA).
     
This program is described in the Catalogue of Domestic Assistance number
13.865, Research for Mothers and Children and 13.242, Division of Basic Brain
     
             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 8
and Behavioral Sciences.  Awards will be made under the authority of the
Public Health Service Act, Title II, Section 301 (Public Law 78-410, as
amended; 42 USC 241) and administered under PAS grant policies and Federal
Regulations 42 CRF part 52 and 45 CRF 74.  This program is not subject to the
intergovernmental review requirements of Executive order 12372 or Health
Systems Agency Review.
     
Inquiries should be directed to:
     
Norman A. Krasnegor, Ph.D.
Chief, Human Learning and Behavior Branch
National Institute of Child Health and Human Development
Executive Plaza North, Room 633
9000 Rockville Pike
Bethesda, MD  20892
Telephone:  (301) 496-6591
     
    OR
     
Rodney Cocking, Ph.D.
Acting Chief, Behavioral Sciences Research Branch
National Institute of Mental Health
Parklawn Building, Room 11C10
5600 Fishers Lane
Rockville, MD  20857
Telephone:  (301) 443-3566

                        ONGOING PROGRAM ANNOUNCEMENTS

ADAMHA SMALL INSTRUMENTATION GRANT PROGRAM
     
P.T. 18; K.W. 0735000
     
Alcohol, Drug Abuse, and Mental Health Administration
     
Application Receipt Date:  June 1, 1990
     
The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) is
announcing the second year of the ADAMHA Small Instrumentation Program (ASIP).
These grants reauthorized by Congress for FY 1990 in Section 501(m) of the
Public Health Service Act, as added to by P.L. 100-690, in response to
findings that much of the research instrumentation in the Nation's principal
universities is either obsolete or poorly maintained.  These findings,
documented in several reports, identified the need for upgrading equipment
currently in use.  The most significant need was for relatively low-cost
pieces of equipment.  To address this problem, ADAMHA established the Small
Instrumentation Program in FY 1989.  Awards are made under authority of Titles
III and V of the PHS Act as amended.  Funds will be provided to
research-intensive institutions currently receiving ADAMHA research support.
The ASIP is not intended to replace requests for equipment in applications for
individual research projects.  Rather, it is intended to help fund items of
equipment that are difficult to justify within the context of an individual
research project but that will upgrade the institution's research
infrastructure.
     
The ADAMHA program has a similar purpose to the National Institutes of Health
Small Instrumentation Program but will operate separately and under slightly
different guidelines because of differences in the infrastructure support
mechanisms available to the two agencies.
     
The ADAMHA program will be funded in FY 1990 at $2,790,000.  The program
provides awards ranging from $20,000 to $100,000 to eligible institutions.
Eligible institutions are those that had five or more active ADAMHA research
or career grants awarded in FY 1989.  At least one of the awards must be from
the following types of developmental awards:  R03, R23, R29, K07, K08, K11,
K20.  The remaining awards may be from this list of grant mechanisms or may be
R01 or R37 grants to make the total of five grant awards needed for
eligibility.  The amount for which your institution may apply was calculated
by a formula based on the $2,790,000 available for the program this year and
on the number of ADAMHA-sponsored awards in the eligible mechanisms at your
institution.  Each eligible institution may submit ONLY ONE application that
incorporates all appropriate equipment requests from that institution.  Thus,
it is essential that institutional officials publicize the availability of
ASIP funds so that ADAMHA-supported investigators in need of small research
instruments are provided the opportunity to indicate their needs for such
equipment to the appropriate institutional official.
     
             NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 9
The equipment requested must be available for use by more than one project
either currently or in the future.  The primary user(s) of the equipment must
be one or more principal investigators of active ADAMHA-supported research
grants, and the specific projects must be cited in the application.
Institutions are strongly urged to include the listed career developmental
projects (i.e., all those other than R01 and R37 grants) in the use of the
equipment.  No indirect costs will be provided and there will be no future
year funding commitment.  The requested funds may be for full or partial
support of one or more pieces of equipment.  In no case, however, may the
total purchase price of a requested piece of equipment be less than $5,000 or
more than $100,000 regardless of the source(s) of funding.  If the total
dollar amount of proposed equipment purchases exceeds the amount for which the
institution is eligible, a statement must be submitted which indicates that
the institution will provide the difference.  Support from this program cannot
be used to purchase items exceeding $100,000 in cost even if costs are shared.
The equipment purchased must be the same as that specified in the ASIP
application.
     
Applications must be received by June 1, 1990.  Detailed application
procedures have been sent to eligible institutions.  Applications will be peer
reviewed by a single ADAMHA-wide committee.  The review criteria are:  Degree
of adherence to the terms of the letter of eligibility and adequacy of the
justification provided for the equipment requested.  The reviewers will
determine whether or not the application is recommended for approval; no
priority scores will be voted.  Applications will be assigned to individual
ADAMHA Institutes for consideration by their National Advisory Councils and
for funding.  The Institutes expect to make the awards in September.
     
Questions concerning this program may be directed to any of the following
persons:
     
Dr. Leslie Isaki
Division of Basic Research
National Institute on Alcohol Abuse and Alcoholism
Room 14C-20
Telephone:  (301) 443-4223
     
Dr. Stephen Szara
Division of Preclinical Research
National Institute on Drug Abuse
Room 10A-31
Telephone:  (301) 443-6300
     
Mr. James Moynihan
Division of Basic Brain and Behavioral Sciences
National Institute of Mental Health
Room 11-95
Telephone:  (301) 443-3107
     
The mailing address for the above individuals is:
     
5600 Fishers Lane
Rockville, MD  20857

SPECIAL EMPHASIS RESEARCH CAREER AWARD IN LABORATORY ANIMAL SCIENCE
     
P.T. 34; K.W. 0201058, 1002027, 0765035, 1002019, 0710070, 1003002
     
National Center for Research Resources
     
Application Receipt Date:  June 1, 1990
     
This is to announce some modifications and clarifications to the guidelines
for the Special Emphasis Research Career Award (SERCA) in Laboratory Animal
Sciences, most recently announced by the National Center for Research
Resources (formerly Division of Research Resources) in 1989.  A summary of
these changes is given below.  Note that there is a single receipt date.
     
AREAS OF CHANGE
     
1.  The requirement for prior training/experience has been increased.
     
2.  An applicant may be enrolled in Ph.D. program.
     
3.  Activities should be focused on a specific research area.

     
            NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 10
4.  The applicant may not have been designated previously as a Principal
Investigator on any research project supported by sources outside his/her
institution.
     
5.  The major advisor and laboratory should be different for pre-versus
post-Ph.D. activities.
     
6.  Specific criteria for review have been included.
     
ADMINISTRATIVE REQUIREMENTS.  The SERCA award is a five-year, nontransferable,
non-renewable award.  The maximum salary from this award may not exceed
$40,000 a year.  Fringe benefits from the award will be based on the salary
awarded by NIH.  Salary supplements are allowable but may not be made from
other Federal sources.  The applicant must agree to devote at least 75 percent
effort to research.  Research support may be requested up to the amount of
$8,000 per year for the first three years and $15,000 per year for the last
two years.  The applicant must agree to keep the Animal Resources Program
(ARP), National Center for Research Resources (NCRR), National Institutes of
Health (NIH), informed of his/her research and training activities for a
period of five years following completion of this support.
     
APPLICANT ELIGIBILITY REQUIREMENTS.  The applicant must hold a degree in
veterinary medicine (D.V.M., V.M.D., or equivalent); be a U.S. citizen,
noncitizen U.S. national, or a noncitizen who has been admitted to the U.S.
for permanent residence; and have at least three years of post-D.V.M.
experience that includes the equivalent of at least two years of full-time (80
percent FTE) training and/or experience in clinical laboratory animal medicine
or comparative pathology in an institution engaged in biomedical
investigation.  The SERCA should not be considered as a mechanism to obtain
the Ph.D. degree.  However, the research performed under the SERCA may be used
to satisfy the thesis requirements for a Ph.D. degree after the qualifying
examination has been passed.  The applicant may not have been a PI on any
research project supported by sources from outside his/her institution.
     
PROGRAM REQUIREMENTS.  The applicant must propose a senior scientist, with
experience in post-doctoral training, as an advisor to guide the first three
years of the award period.  The advisor must agree to be available to counsel,
advise, and monitor the applicant's research at frequent intervals.  In
addition, three letters of reference are required from investigators in the
applicant's field of scientific interest or in a closely related field.
Different advisors for pre- and post- Ph.D. work should be identified.
     
In the initial application, the applicant and advisor should describe an
overall concept or research hypothesis that will be the focus of the award and
provide the framework around which the desired training will be obtained.  A
specific, detailed plan for enhancing the applicant's research skills during
the first three years of the award and a well developed outline of a
meritorious research program for the final two years of the award must be
included.  As part of the annual progress report for the 03 year, the awardee
must provide a detailed research plan for the last two years (years 04 and
05).  This proposal will be evaluated for scientific merit.  This evaluation,
along with the progress made throughout the initial three-year period, will be
used to determine the applicant's eligibility for continued funding for the
fourth and fifth years.
     
CRITERIA FOR REVIEW.  In the review of the application for scientific merit,
particular attention will be given to the candidate's prior training and
experience, career potential, research career development plans, proposed
research, environment, reference reports, and other relevant information.  The
application must clearly demonstrate that the award will enhance the
candidate's development as an independent investigator.
     
A letter of interest to the Branch Director, outlining the applicant's
training, research interests, and proposed SERCA program, is not a
prerequisite for applying but is encouraged.  June 1 will be the only
application receipt date.  Detailed background information and application
procedures may be obtained from:
     
Director
Laboratory Animal Sciences Branch, ARP
National Center for Research Resources
National Institutes of Health
Westwood Building, Room 857
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-5175

     
            NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 11
This program is described in the Catalog of Federal Domestic Assistance No.
13.306, Laboratory Animal Sciences and Primate Research.  Awards will be made
under the authority of the Public Health Service Act, Title III, Section 301
(Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant
policies and Federal Regulations 42 CFR Part 52, and 45 CFR Part 74.  This
program is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

NEUROENDOCRINOLOGY OF HUMAN STRESS
     
P.T. 34; K.W. 0785105, 0715195, 0710085, 1002008, 1002004, 1002021, 0710070
     
National Institute of Diabetes, Digestive and Kidney Diseases
     
PURPOSE
     
The National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK)
invites investigator-initiated research grant applications (R01) to advance
understanding of the interaction of endocrine, central nervous system (CNS),
and immunological response(s) to stress.
     
DISCIPLINES AND EXPERTISE
     
Interdisciplinary approaches may be needed for this study with expertise
required in several of the following areas:  neuroendocrinology, cell and
molecular biology, histology, neurophysiology, immunology, and peptide and/or
steroid biochemistry.
     
BACKGROUND
     
Corticotropin releasing factor (CRF) is the hypothalamic hormone responsible
for stimulating the release of pituitary preopiomelanocortin (POMC)-derived
neuropeptides, including ACTH and B-endorphin.  In addition to its well-known
role in initiating hypothalamic-pituitary-adrenal (HPA) axis responses to
acute stress and modulating long-term adaptation to chronic stress, CRF has
been found to act within other areas of the CNS to modulate behaviors
associated with the response and adaptation to stress.  It has been suggested
that CRF acts to integrate the overall interrelated endocrine, neural, and
behavioral responses to stress.  In addition, there is preliminary, but
provocative evidence for bidirectional communication between the immune,
endocrine, and central nervous systems mediated by peptide hormones and
receptors common to these systems.  A variety of neural cells secrete
interleukins and growth factors, with neuronal cell growth and proliferation
regulated by these monokines and growth factors.  More recently evidence has
been presented that lymphocytes produce neuropeptides including endorphins,
enkephalins, vasoactive intestinal peptide (VIP), substance P and
corticotropin, although the physiological significance of this capability has
yet to be established.  These cells also express receptors for neuropeptides
and respond to these hormones.  The same peptides may regulate production of
corticotropin in lymphocytes and in the pituitary.  Therefore, one element of
the immune system's response to stresses, such as infection, inflammation,
toxins, tumors, trauma and possibly psychological stress, may involve
activation of the HPA axis at multiple levels.  It has become apparent that
acute infection acts via CRF in initiating activation of the neuroendocrine
system as part of the response to this stress.  Recent information indicates
that immune system cytokines, including IL (interluekin)-1, IL-2, thymosin,
and thymopoietin, interact at central hypothalamic and/or anterior pituitary
sites to regulate release of ACTH with consequent effects on adrenal
glucocorticoid release.  These data have been interpreted to suggest that
cytokine action at the level of CRF release links the acute response to
inflammation to the stress response.  Many questions remain, including that of
the cellular and molecular mechanisms of action of CRF on CNS centers and the
role(s) and mechanism of action of immune effectors on the HPA axis and vice
versa.  Finally, demonstration of a clear biological role for the
interrelationship between the neuroendocrine and immune systems remains to be
established.
     
OBJECTIVES
     
This solicitation is intended to stimulate research:  1) that will result in
new understandings of the role of CRF in modulation of the neuroendocrine and
behavioral responses to stress; and 2) into the interaction between the immune
system and the neuroendocrine system in mediating the endocrine response to
acute and chronic stress.

     
     
            NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 12
SCOPE
     
Some examples of research topics that would be considered responsive to this
solicitation include the following:
     
  o  studies of the central nervous system effects of CRF, including
     identification of the cellular and neuronal centers/networks that
     are part of the response(s) to CRF.
     
  o  regulation of CRF production and/or release by neuropeptides and/or
     immune effectors.
     
  o  identification of the specific cells in the hypothalamus and/or
     anterior pituitary that respond to immune effectors and the role of
     CRF and other neuropeptides in modulating the responses of these
     cells.
     
  o  elucidation of the mechanism(s) of response, including receptors
     involved, signal transduction pathways, and cytoplasmic and/or
     nuclear responses of the target cells.
     
  o  effects of neuropeptides and immune cell effectors on POMC-derived
     peptide release from the pituitary.
     
  o  effects of CRF, ACTH, or adrenal glucocorticoids on immune effector
     cell production and/or release of modulators.
     
  o  identification of the neuropeptides produced in the immune system,
     as well as characterization of neuropeptide effects on the immune
     system and lymphocytic functions.
     
  o  establishment of the functional significance of CNS and
     neuroendocrine involvement in modulation of the immune system and
     vice versa.
     
These areas of interest are not listed in any order or priority.  They are
only suggested examples of areas of research.  Applicants are encouraged to
propose other areas which are related to the objectives and scope described
above.
     
MECHANISM OF SUPPORT
     
The mechanism of support for this program will be the grant-in-aid.  The
regulations (Code of Federal Regulation, Title 42, Part 52 and, as applicable
to the state and local governments, Title 45, Part 74) and policies which
govern the research grant programs of the National Institutes of Health will
prevail.  Although this solicitation is included in the sponsoring Institute's
funding plans for Fiscal Year 1991, support for this solicitation is
contingent upon receipt of appropriated funds for this purpose.  Since a
variety of approaches would represent valid responses to this solicitation, it
is anticipated that there will be a range of costs among individual grants
awarded.  With respect to post-award administration, the current policies and
requirements that govern the regular research grant programs of the NIH will
prevail.
     
REVIEW PROCEDURES AND CRITERIA
     
Assignment of Applications
     
Applications will be received by the NIH, Division of Research Grants (DRG),
referred to an appropriate Initial Review Group (IRG) for scientific merit
review, and assigned to individual Institutes for possible funding.  Referral
decisions will be governed by normal programmatic considerations as specified
in the Referral Guidelines of the NIH, DRG.  Some applications may receive
dual assignment.
     
Review Procedures
     
Applications in response to this solicitation will be reviewed on a nationwide
basis in accord with the usual NIH peer review procedures.  Applications will
first be reviewed for scientific and technical merit by an IRG composed
primarily of non-federal scientific consultants, and then by the National
Advisory Council of the appropriate Institute(s).  The review criteria
customarily employed by the NIH for regular research grant applications will
prevail.

     
     
            NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 13
Review Criteria
     
The factors to be considered in the evaluation of scientific merit of each
application will be those used in the review of traditional research project
grant applications, including the novelty, originality, and feasibility of the
approach; the training, experience, and research competence of the
investigator(s); the adequacy of the experimental design; the suitability of
the facilities; and the appropriateness of the requested budget to the work
proposed.
     
METHOD OF APPLYING
     
Format for Applications
     
Applications should be submitted on form PHS 398 (rev.  10/88), which is
available from an applicant institution's Office of Sponsored Research or from
the NIH, DRG.  Use the conventional format for research project grant
applications and ensure that the points identified in this Program
Announcement (PA) in the section on "Review Procedures and Criteria" are
fulfilled.  To identify the application as a response to this PA, check "yes"
on item two of page one of the application and enter the title
"Neuroendocrinology of Human Stress."
     
Deadline
     
Applications will be accepted in accordance with the announced receipt dates
for new applications (see receipt dates and review schedule in application
kits).
     
Application Procedure
     
The original and six copies of the application should be sent or delivered to:
     
Application Receipt
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
     
Inquiries
     
For further information, investigators are encouraged to contact:
     
Ronald N. Margolis, Ph.D.
Director, Endocrinology Research Program
Division of Diabetes, Endocrinology, and Metabolic Diseases
NIDDK/NIH
Westwood Bldg., Room 605
Bethesda, MD 20892
Telephone:  (301) 496-7504
     
This program is described in the Catalog of Federal Domestic Assistance
13.846, Arthritis, Bone and Skin Diseases Research and No. 13.847, Diabetes,
Endocrinology, and Metabolism, No. 13.855.  Awards will be made under the
authority of the Public Health Service Act, Title III, Section 301 (Public Law
78-410, as amended; 42 USC 241) and administered under PHS grant policies and
Federal Regulations 42 CFR part 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency Review.

                                   ERRATUM

NOTICE OF SOLICITATION OF PUBLIC COMMENTS FOR THE NATIONAL PANEL FOR RESEARCH
IN NEUROLOGICAL DISORDERS
     
P.T. 42; K.W. 0715138, 0705010, 1002030, 0710030
     
National Institute of Neurological Disorders and Stroke
     
This notice, as published in the NIH Guide for Grants and Contracts on March
23, 1990, Vol. 19, No. 12, contained an incorrect telephone number.  The
following is the correct information:
     
Ms. Johanna McDonough
Telephone:  (301) 986-4870

            NIH GUIDE - Vol. 19, No. 13, March 30, 1990 - Page 14